Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.

The insolvent genetic analysis company 23andme is taken over by a pharmaceutical company that wants to continue the business and has promised data protection.

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations as well as its biobank of collected samples. The deal, which is subject to court approval, does not cover 23andMe’s Lemonaid Health telemedicine and virtual pharmacy business.

Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue